{"transactions":[{"id":3691884,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":105497,"kind":"organization","name":"SVLSF VI, LLC","position":1,"cik":"0001717728","reported_name":"SVLSF VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":2,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":3,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105496,"kind":"organization","name":"SV Life Sciences Fund VI (GP), L.P.","position":4,"cik":"0001717730","reported_name":"SV Life Sciences Fund VI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-01-18T17:00:47.000Z","date":"2019-01-16","kind":"other","acquired":false,"shares":26660,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See\nFootnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"SV Life Sciences Fund VI Strategic Partners, L.P. (\"SV Life SP LP\") distributed the shares to its limited partners on a pro rata basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by SV Life SP LP. SV Fund VI GP is the general partner of SV Life SP LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. Each of SV Fund VI GP, and SVLSF VI, LLC disclaims beneficial ownership of the shares owned directly by SV Life SP LP, except to the extent of any pecuniary interest therein."}],"balance_after":63913,"source":{"system":"sec-edgar","filing":"0000899243-19-001495","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1717728/000089924319001495/doc4.xml","form_type":"4"}},{"id":3691883,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":105497,"kind":"organization","name":"SVLSF VI, LLC","position":1,"cik":"0001717728","reported_name":"SVLSF VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":2,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":3,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105496,"kind":"organization","name":"SV Life Sciences Fund VI (GP), L.P.","position":4,"cik":"0001717730","reported_name":"SV Life Sciences Fund VI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-01-18T17:00:47.000Z","date":"2019-01-16","kind":"other","acquired":false,"shares":778663,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See\nFootnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"SV Life Sciences Fund VI, L.P. (\"SV Life LP\") distributed the shares to its limited partners on a pro rata basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by SV Life LP. SV Life Sciences Fund VI (GP), L.P. (\"SV Fund VI GP\") is the general partner of SV Life LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. Each of SV Fund VI GP and SVLSF VI, LLC disclaims beneficial ownership of the shares owned directly by SV Life LP, except to the extent of any pecuniary interest therein."}],"balance_after":1866791,"source":{"system":"sec-edgar","filing":"0000899243-19-001495","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1717728/000089924319001495/doc4.xml","form_type":"4"}},{"id":3884174,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":105497,"kind":"organization","name":"SVLSF VI, LLC","position":1,"cik":"0001717728","reported_name":"SVLSF VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":2,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":3,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105496,"kind":"organization","name":"SV Life Sciences Fund VI (GP), L.P.","position":4,"cik":"0001717730","reported_name":"SV Life Sciences Fund VI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-06-25T18:16:19.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":61908,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Represents the total number of shares of Common Stock received by SV Life Sciences Fund VI Strategic Partners, L.P. (\"SV Life SP LP\")  upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by SV Life SP LP. SV Health Investors, LLC is the Manager of SV Life SP LP. SV Fund VI GP is the general partner of SV Life SP LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life SP LP, except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":14982},"source":{"system":"sec-edgar","filing":"0000899243-18-017965","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1717728/000089924318017965/doc4.xml","form_type":"4"}},{"id":3884173,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":105497,"kind":"organization","name":"SVLSF VI, LLC","position":1,"cik":"0001717728","reported_name":"SVLSF VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":2,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":3,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105496,"kind":"organization","name":"SV Life Sciences Fund VI (GP), L.P.","position":4,"cik":"0001717730","reported_name":"SV Life Sciences Fund VI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-06-25T18:16:19.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":1808211,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Represents the total number of shares of Common Stock received by SV Life Sciences Fund VI Strategic Partners, L.P. (\"SV Life SP LP\")  upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by SV Life LP. SV Health Investors, LLC is the Manager of SV Life LP. SV Life Sciences Fund VI (GP), L.P., (\"SV Fund VI GP\") is the general partner of SV Life LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life LP,  except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":437611},"source":{"system":"sec-edgar","filing":"0000899243-18-017965","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1717728/000089924318017965/doc4.xml","form_type":"4"}},{"id":3884172,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":105497,"kind":"organization","name":"SVLSF VI, LLC","position":1,"cik":"0001717728","reported_name":"SVLSF VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":2,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":3,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105496,"kind":"organization","name":"SV Life Sciences Fund VI (GP), L.P.","position":4,"cik":"0001717730","reported_name":"SV Life Sciences Fund VI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-06-25T18:16:19.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":312341,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Represents the total number of shares of Common Stock received by SV Life Sciences Fund VI Strategic Partners, L.P. (\"SV Life SP LP\")  upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by SV Life SP LP. SV Health Investors, LLC is the Manager of SV Life SP LP. SV Fund VI GP is the general partner of SV Life SP LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life SP LP, except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":75591},"source":{"system":"sec-edgar","filing":"0000899243-18-017965","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1717728/000089924318017965/doc4.xml","form_type":"4"}},{"id":3884171,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":105497,"kind":"organization","name":"SVLSF VI, LLC","position":1,"cik":"0001717728","reported_name":"SVLSF VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":2,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":3,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105496,"kind":"organization","name":"SV Life Sciences Fund VI (GP), L.P.","position":4,"cik":"0001717730","reported_name":"SV Life Sciences Fund VI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-06-25T18:16:19.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":9122809,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Represents the total number of shares of Common Stock received by SV Life Sciences Fund VI Strategic Partners, L.P. (\"SV Life SP LP\")  upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by SV Life LP. SV Health Investors, LLC is the Manager of SV Life LP. SV Life Sciences Fund VI (GP), L.P., (\"SV Fund VI GP\") is the general partner of SV Life LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life LP,  except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2207843},"source":{"system":"sec-edgar","filing":"0000899243-18-017965","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1717728/000089924318017965/doc4.xml","form_type":"4"}},{"id":3884170,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":105497,"kind":"organization","name":"SVLSF VI, LLC","position":1,"cik":"0001717728","reported_name":"SVLSF VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":2,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":3,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105496,"kind":"organization","name":"SV Life Sciences Fund VI (GP), L.P.","position":4,"cik":"0001717730","reported_name":"SV Life Sciences Fund VI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-25T18:16:19.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":14982,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the total number of shares of Common Stock received by SV Life SP LP upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by SV Life SP LP. SV Health Investors, LLC is the Manager of SV Life SP LP. SV Fund VI GP is the general partner of SV Life SP LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life SP LP, except to the extent of any pecuniary interest therein."}],"balance_after":90573,"source":{"system":"sec-edgar","filing":"0000899243-18-017965","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1717728/000089924318017965/doc4.xml","form_type":"4"}},{"id":3884169,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":105497,"kind":"organization","name":"SVLSF VI, LLC","position":1,"cik":"0001717728","reported_name":"SVLSF VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":2,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":3,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105496,"kind":"organization","name":"SV Life Sciences Fund VI (GP), L.P.","position":4,"cik":"0001717730","reported_name":"SV Life Sciences Fund VI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-25T18:16:19.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":437611,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the total number of shares of Common Stock received by SV Life LP upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by SV Life LP. SV Health Investors, LLC is the Manager of SV Life LP. SV Life Sciences Fund VI (GP), L.P., (\"SV Fund VI GP\") is the general partner of SV Life LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life LP,  except to the extent of any pecuniary interest therein."}],"balance_after":2645454,"source":{"system":"sec-edgar","filing":"0000899243-18-017965","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1717728/000089924318017965/doc4.xml","form_type":"4"}},{"id":3884168,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":105497,"kind":"organization","name":"SVLSF VI, LLC","position":1,"cik":"0001717728","reported_name":"SVLSF VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":2,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":3,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105496,"kind":"organization","name":"SV Life Sciences Fund VI (GP), L.P.","position":4,"cik":"0001717730","reported_name":"SV Life Sciences Fund VI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-25T18:16:19.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":75591,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the total number of shares of Common Stock received by SV Life Sciences Fund VI Strategic Partners, L.P. (\"SV Life SP LP\")  upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by SV Life SP LP. SV Health Investors, LLC is the Manager of SV Life SP LP. SV Fund VI GP is the general partner of SV Life SP LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life SP LP, except to the extent of any pecuniary interest therein."}],"balance_after":75591,"source":{"system":"sec-edgar","filing":"0000899243-18-017965","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1717728/000089924318017965/doc4.xml","form_type":"4"}},{"id":3884167,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":105497,"kind":"organization","name":"SVLSF VI, LLC","position":1,"cik":"0001717728","reported_name":"SVLSF VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":2,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":3,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105496,"kind":"organization","name":"SV Life Sciences Fund VI (GP), L.P.","position":4,"cik":"0001717730","reported_name":"SV Life Sciences Fund VI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-25T18:16:19.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":2207843,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the total number of shares of Common Stock received by SV Life Sciences Fund VI, L.P. (\"SV Life LP\") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by SV Life LP. SV Health Investors, LLC is the Manager of SV Life LP. SV Life Sciences Fund VI (GP), L.P., (\"SV Fund VI GP\") is the general partner of SV Life LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life LP,  except to the extent of any pecuniary interest therein."}],"balance_after":2207843,"source":{"system":"sec-edgar","filing":"0000899243-18-017965","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1717728/000089924318017965/doc4.xml","form_type":"4"}},{"id":4156464,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":50477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F9","text":"These shares are owned directly by SV Life Sciences Fund VI Strategic Partners, L.P. (\"SVLS VI SPP\"). SVLS VI GP is the general partner of SVLS VI SPP. The general partner of SVLS VI GP is SVLSF VI, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III, Paul LaViolette, Thomas Flynn, and Michael Ross are members of the investment committee of SVLSF VI, LLC. SVLS VI GP, SVLSF VI, LLC and each of the individuals comprising the SVLSF VI, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS VI SPP. Each of SVLS VI GP, SVLSF VI, LLC and the individual members of the SVLSF VI, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":14789},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156463,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":1474348,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"These shares are owned directly by SV Life Sciences Fund VI, L.P. (\"SVLS VI LP\"). SV Life Sciences Fund VI (GP), LP (\"SVLS VI GP\") is the general partner of SVLS VI LP. The general partner of SVLS VI GP is SVLSF VI, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III, Paul LaViolette, Thomas Flynn and Michael Ross are members of the investment committee of SVLSF VI, LLC. SVLS VI GP, SVLSF VI, LLC and each of the individuals comprising the SVLSF VI, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS VI LP. Each of SVLS VI GP, SVLSF VI, LLC and the individual members of the SVLSF VI, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":431980},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156462,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":14635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4288},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156461,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":692552,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":202915},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156460,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":4747,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2365},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156459,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":224665,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":111955},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156458,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":15246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6806},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156457,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":721402,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":322102},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156456,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":14587,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5219},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156455,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":690259,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":247010},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156454,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":1380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":404},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156453,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":65287,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":19128},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156452,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"purchase","acquired":true,"shares":16552,"price":10,"value":165520.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F9","text":"These shares are owned directly by SV Life Sciences Fund VI Strategic Partners, L.P. (\"SVLS VI SPP\"). SVLS VI GP is the general partner of SVLS VI SPP. The general partner of SVLS VI GP is SVLSF VI, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III, Paul LaViolette, Thomas Flynn, and Michael Ross are members of the investment committee of SVLSF VI, LLC. SVLS VI GP, SVLSF VI, LLC and each of the individuals comprising the SVLSF VI, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS VI SPP. Each of SVLS VI GP, SVLSF VI, LLC and the individual members of the SVLSF VI, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":1868961,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156451,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"purchase","acquired":true,"shares":483448,"price":10,"value":4834480.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"These shares are owned directly by SV Life Sciences Fund VI, L.P. (\"SVLS VI LP\"). SV Life Sciences Fund VI (GP), LP (\"SVLS VI GP\") is the general partner of SVLS VI LP. The general partner of SVLS VI GP is SVLSF VI, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III, Paul LaViolette, Thomas Flynn and Michael Ross are members of the investment committee of SVLSF VI, LLC. SVLS VI GP, SVLSF VI, LLC and each of the individuals comprising the SVLSF VI, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS VI LP. Each of SVLS VI GP, SVLSF VI, LLC and the individual members of the SVLSF VI, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":1852409,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156450,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":14789,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F9","text":"These shares are owned directly by SV Life Sciences Fund VI Strategic Partners, L.P. (\"SVLS VI SPP\"). SVLS VI GP is the general partner of SVLS VI SPP. The general partner of SVLS VI GP is SVLSF VI, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III, Paul LaViolette, Thomas Flynn, and Michael Ross are members of the investment committee of SVLSF VI, LLC. SVLS VI GP, SVLSF VI, LLC and each of the individuals comprising the SVLSF VI, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS VI SPP. Each of SVLS VI GP, SVLSF VI, LLC and the individual members of the SVLSF VI, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":1368961,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156449,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":431980,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"These shares are owned directly by SV Life Sciences Fund VI, L.P. (\"SVLS VI LP\"). SV Life Sciences Fund VI (GP), LP (\"SVLS VI GP\") is the general partner of SVLS VI LP. The general partner of SVLS VI GP is SVLSF VI, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III, Paul LaViolette, Thomas Flynn and Michael Ross are members of the investment committee of SVLSF VI, LLC. SVLS VI GP, SVLSF VI, LLC and each of the individuals comprising the SVLSF VI, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS VI LP. Each of SVLS VI GP, SVLSF VI, LLC and the individual members of the SVLSF VI, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":1354172,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156448,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":4288,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":922192,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156447,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":202915,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":917904,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156446,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":2365,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":714989,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156445,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":111955,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":712624,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156444,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":6806,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":600669,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156443,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":322102,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":593863,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156442,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":5219,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":271761,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156441,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":247010,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":266542,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156440,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":404,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":19532,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156439,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":19128,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":19128,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}}]}